Oxcarbazepine for self-mutilating bulimic patients

Córdas, Taki Athanássios; Tavares, Hermano; Calderoni, Douglas Motta; Stump, Gabriela Viegas; Ribeiro, Rafael Bernardon

doi:10.1017/s1461145706006687

Cited by 16 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in turn, the fact that other classes of drugs with no or no significant D1 antagonistic activity were described to also reduce significantly NSSI [Stanley et al 2010;Hawton et al 1999;Cordás et al 2006], strongly suggests that not only D1 receptors but other neurotransmitter receptors/ systems are involved in the assumingly complex pathobiology of NSSI.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the availability of elaborate psychotherapeutic NSSI interventions [Hawton et al 1999], this burdensome symptom, which is associated with an increased risk for suicide attempts, is often treatment refractory [Stanley et al 2010]. Inter alia, antidepressants, especially serotonin reuptake inhibitors, modulators of the endogenous opioid system and various other drugs such as oxcarbazepine were discussed to be potentially effective in NSSI therapy [Stanley et al 2010;Hawton et al 1999;Cordás et al 2006]. In addition, interestingly, there are several reports on the efficacy of atypical antipsychotics (AAs) in NSSI treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases

Wollweber

Keck

Schmidt

2015

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Introduction: There is no drug treatment for nonsuicidal self-injury (NSSI), a highly prevalent and burdensome symptom of several psychiatric diseases like posttraumatic stress disorder (PTSD), personality disorders, and major depression (MD). Methods:Here, we present a retrospective series of three patients demonstrating a persistent remission in MD-associated NSSI in response to treatment with antipsychotics possessing marked D1 receptor antagonistic activity. Results: To the best of the authors' knowledge, the case series presented is only the second clinical paper suggesting a role for D1 antagonists in NSSI drug therapy. Conclusions: Together with previously published data from rodent models, the findings suggest a role for D1 antagonists in NSSI drug therapy and hence for the D1 receptor in NSSI pathogenesis. This conclusion is limited by the facts that the patients presented here received polypharmacy and that the D1 receptor antagonistic antipsychotics suggested here as effective 'anti-auto-aggressants' do not address D1 receptors only but multiple neurotransmitter receptors/systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases

Wollweber

Keck

Schmidt

2015

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Results showed a benefit from oxcarbazepine compared with placebo on OAS-M scores and patient-rated global improvement. Cordas et al (2006) [69] describe 2 cases of severe bulimia nervousa and BPD, in which self-mutilating behavior was successfully controlled after oxcarbazepine treatment.…”

Section: Carbamazepine and Oxcarbazepinementioning

confidence: 99%

Antiepileptic Drugs for the Treatment of Impulsivity

Berlin

2008

CPSR

View full text Add to dashboard Cite

Evidence is reviewed here which suggests that antiepileptic drugs (AEDs) may be effective for the treatment of impulsivity across a range of psychiatric disorders and for impulse control and cluster B personality disorders in particular. AEDs may be effective for the treatment of the brain circuitry related to impulsivity, by modulating GABA, glutamate, serotonin, and norepinephrine. It is suggested that interventions should be directed at the brain circuitry which modulates core symptoms like impulsivity that may be shared across disorders, rather than the disorder itself. In addition to these core symptom domains, clinicians should identify comorbid conditions and associated symptoms related to brain systems as they can also influence overall treatment response. The increasing experience of psychiatrists in treating impulse control disorders, cluster B personality disorders, and impulsivity across disorders should complement the knowledge obtained from research. This will lead to a better understanding of the brain mechanisms underlying impulsive symptom domains within disorders and to more targeted treatments with improved outcomes.

show abstract

“…14 The effectiveness of oxcarbazepine has also been investigated for treating mania, bipolar II and borderline personality disorders (BPD). [15][16][17] Cordas et al 18 reported using oxcarbafor BED. The research protocol received approval from the ethical committee of the University of Turin, and the administration of the drug began after all patients gave written informed consent.…”

Section: Introductionmentioning

confidence: 99%

Oxcarbazepine for the treatment of binge eating disorder: a case series

et al. 2008

View full text Add to dashboard Cite

We present a case series of nine obese outpatients with a diagnosis of binge eating disorder who were treated with a flexible dose of the anticonvulsant oxcarbazepine. The drug has not previously been used to treat this disorder. Five patients dropped out at various points of the study, giving only fragmented data. Where data were available, all patients reported side effects (n=7) and some showed a reduction (n=4) or no change (n=3) in binge episode frequency. Some patients lost weight over the study period (n=3; range, 3-5 kg); others showed no change (n=2) or an increase in weight (n=3; range, 1.8-2.9 kg). Our results were inconsistent, but the drug was effective for some patients who showed marked impulsivity in eating behaviours and depressive symptoms.

show abstract

Oxcarbazepine for self-mutilating bulimic patients

Cited by 16 publications

References 9 publications

Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases

Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases

Antiepileptic Drugs for the Treatment of Impulsivity

Oxcarbazepine for the treatment of binge eating disorder: a case series

Contact Info

Product

Resources

About